Application of Clinical and Molecular Profiling Data to Improve Patient Outcomes in Psoriatic Arthritis

HIPPOCRATES Consortium; Oliver FitzGerald; Frank Behrens; Anne Barton; Heidi Bertheussen; Bruno Boutouyrie- Dumont; Laura  Coates; Owen  Davies; Maarten De Wit; Filippo  Fagni; Carl S Goodyear; Robert  Gurke; Lisa  Hahnfeld; Christine  Huppertz; Vassilios Ioannidis; Mark Ibberson; Arnon  Katz; Maximilian  Klippstein; Michaela  Koehm; Shimon  Korish; Sina  Mackay; David Martin; Denis  O'Sullivan; Khadijah Patel; Stefan  Rueping; Georg Schett; Klaus  Scholich; Jochen M.  Schwenk; Stefan  Siebet; David Simon; Arani Vivekanantham; Stephen R. Pennington

doi:10.1177/1759720X23119231

Application of Clinical and Molecular Profiling Data to Improve Patient Outcomes in Psoriatic Arthritis

HIPPOCRATES Consortium, Oliver FitzGerald, Frank Behrens, Anne Barton, Heidi Bertheussen, Bruno Boutouyrie- Dumont, Laura Coates, Owen Davies, Maarten De Wit, Filippo Fagni, Carl S Goodyear, Robert Gurke, Lisa Hahnfeld, Christine Huppertz, Vassilios Ioannidis, Mark Ibberson, Arnon Katz, Maximilian Klippstein, Michaela Koehm, Shimon KorishSina Mackay, David Martin, Denis O'Sullivan, Khadijah Patel, Stefan Rueping, Georg Schett, Klaus Scholich, Jochen M. Schwenk, Stefan Siebet, David Simon, Arani Vivekanantham, Stephen R. Pennington

Division of Musculoskeletal & Dermatological Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-center studies have certainly contributed to our understanding of disease pathogenesis but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centers experienced in PsA research, 5 pharmaceutical industry partners, 3 small/medium sized industry partners and 2 patient representative organisations. In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing, and treating PsA allowing for better short-term and long-term outcomes

Original language	English
Journal	Therapeutic Advances in Musculoskeletal Disease
DOIs	https://doi.org/10.1177/1759720X23119231
Publication status	Published - 8 Sept 2023

Access to Document

10.1177/1759720X23119231Licence: CC BY-NC

Cite this

HIPPOCRATES Consortium, FitzGerald, O., Behrens, F., Barton, A., Bertheussen, H., Dumont, B. B., Coates, L., Davies, O., De Wit, M., Fagni, F., Goodyear, C. S., Gurke, R., Hahnfeld, L., Huppertz, C., Ioannidis, V., Ibberson, M., Katz, A., Klippstein, M., Koehm, M., ... Pennington, S. R. (2023). Application of Clinical and Molecular Profiling Data to Improve Patient Outcomes in Psoriatic Arthritis. Therapeutic Advances in Musculoskeletal Disease. https://doi.org/10.1177/1759720X23119231

@article{0e22bd3d6b8343c694381cac62303d84,

title = "Application of Clinical and Molecular Profiling Data to Improve Patient Outcomes in Psoriatic Arthritis",

abstract = "Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-center studies have certainly contributed to our understanding of disease pathogenesis but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centers experienced in PsA research, 5 pharmaceutical industry partners, 3 small/medium sized industry partners and 2 patient representative organisations. In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing, and treating PsA allowing for better short-term and long-term outcomes",

author = "{HIPPOCRATES Consortium} and Oliver FitzGerald and Frank Behrens and Anne Barton and Heidi Bertheussen and Dumont, {Bruno Boutouyrie-} and Laura Coates and Owen Davies and {De Wit}, Maarten and Filippo Fagni and Goodyear, {Carl S} and Robert Gurke and Lisa Hahnfeld and Christine Huppertz and Vassilios Ioannidis and Mark Ibberson and Arnon Katz and Maximilian Klippstein and Michaela Koehm and Shimon Korish and Sina Mackay and David Martin and Denis O'Sullivan and Khadijah Patel and Stefan Rueping and Georg Schett and Klaus Scholich and Schwenk, {Jochen M.} and Stefan Siebet and David Simon and Arani Vivekanantham and Pennington, {Stephen R.}",

year = "2023",

month = sep,

day = "8",

doi = "10.1177/1759720X23119231",

language = "English",

journal = "Therapeutic Advances in Musculoskeletal Disease",

issn = "1759-720X",

publisher = "Sage Publications Ltd",

}

HIPPOCRATES Consortium, FitzGerald, O, Behrens, F, Barton, A, Bertheussen, H, Dumont, BB, Coates, L, Davies, O, De Wit, M, Fagni, F, Goodyear, CS, Gurke, R, Hahnfeld, L, Huppertz, C, Ioannidis, V, Ibberson, M, Katz, A, Klippstein, M, Koehm, M, Korish, S, Mackay, S, Martin, D, O'Sullivan, D, Patel, K, Rueping, S, Schett, G, Scholich, K, Schwenk, JM, Siebet, S, Simon, D, Vivekanantham, A & Pennington, SR 2023, 'Application of Clinical and Molecular Profiling Data to Improve Patient Outcomes in Psoriatic Arthritis', Therapeutic Advances in Musculoskeletal Disease. https://doi.org/10.1177/1759720X23119231

TY - JOUR

T1 - Application of Clinical and Molecular Profiling Data to Improve Patient Outcomes in Psoriatic Arthritis

AU - HIPPOCRATES Consortium

AU - FitzGerald, Oliver

AU - Behrens, Frank

AU - Barton, Anne

AU - Bertheussen, Heidi

AU - Dumont, Bruno Boutouyrie-

AU - Coates, Laura

AU - Davies, Owen

AU - De Wit, Maarten

AU - Fagni, Filippo

AU - Goodyear, Carl S

AU - Gurke, Robert

AU - Hahnfeld, Lisa

AU - Huppertz, Christine

AU - Ioannidis, Vassilios

AU - Ibberson, Mark

AU - Katz, Arnon

AU - Klippstein, Maximilian

AU - Koehm, Michaela

AU - Korish, Shimon

AU - Mackay, Sina

AU - Martin, David

AU - O'Sullivan, Denis

AU - Patel, Khadijah

AU - Rueping, Stefan

AU - Schett, Georg

AU - Scholich, Klaus

AU - Schwenk, Jochen M.

AU - Siebet, Stefan

AU - Simon, David

AU - Vivekanantham, Arani

AU - Pennington, Stephen R.

PY - 2023/9/8

Y1 - 2023/9/8

N2 - Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-center studies have certainly contributed to our understanding of disease pathogenesis but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centers experienced in PsA research, 5 pharmaceutical industry partners, 3 small/medium sized industry partners and 2 patient representative organisations. In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing, and treating PsA allowing for better short-term and long-term outcomes

AB - Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-center studies have certainly contributed to our understanding of disease pathogenesis but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centers experienced in PsA research, 5 pharmaceutical industry partners, 3 small/medium sized industry partners and 2 patient representative organisations. In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing, and treating PsA allowing for better short-term and long-term outcomes

U2 - 10.1177/1759720X23119231

DO - 10.1177/1759720X23119231

M3 - Article

SN - 1759-720X

JO - Therapeutic Advances in Musculoskeletal Disease

JF - Therapeutic Advances in Musculoskeletal Disease

ER -

Application of Clinical and Molecular Profiling Data to Improve Patient Outcomes in Psoriatic Arthritis

Abstract

Access to Document

Fingerprint

Cite this